Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 10/20 | 0.47 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.36 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3083548 | 0.87 | CSF1R (0.48) | CSF1RACMSDRECQLPTGS2 | |
| Trifluoroacetic Acid SCHEMBL3082958 | 0.83 | PTGS2 (0.44) | CSF1RACMSDGRM2PTGS2 | |
| SCHEMBL4187143 | 0.80 | CSF1R (0.53) | CSF1RGRM2PTGS2 | |
| SCHEMBL4184235 | 0.80 | CSF1R (0.54) | CSF1RPLA2G10PLA2G2ASLCO1B1GRM2 | |
| Trifluoroacetic Acid SCHEMBL4344857 | 0.79 | CSF1R (0.59) | CSF1R | |
| SCHEMBL3083546 | 0.79 | CSF1R (0.60) | CSF1R | |
| SCHEMBL3086411 | 0.79 | CSF1R (0.43) | CSF1RGRM2 | |
| SCHEMBL3085270 | 0.78 | CSF1R (0.47) | CSF1RACMSDPLA2G10PLA2G2ASLCO1B1 | |
| SCHEMBL4187309 | 0.77 | CSF1R (0.51) | CSF1RACMSDPLA2G10PLA2G2ASLCO1B1 | |
| SCHEMBL4182581 | 0.76 | CSF1R (0.56) | CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | claimed |
| US-20060258666-A1 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-16 | — | — | US | claimed |
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-20060258666-A1 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258666-A1 | c-fms kinase inhibitors | FLT3, FES, FER | CSF1R 111/4885ACMSD 4123/4885PLA2G10 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.